Good data is essential for a successful study. Whilst analysis is important, standardisation in the clinic is imperative.Although many may claim they are specialists in conducting TQT studies, few have the data to back this up. Our published data shows that over the past decade, Richmond Pharmacology�s studies have consistently produced less variability of QT measurements when compared directly with our competitors. This confirms that we are the leading research unit for cardiac safety studies - either as a one stop solution or in conjunction with our preferred partner core labs.At Richmond Pharmacology our mantra is good data in equals good data out.Our 10th Birthday PromiseWe are so confident and proud of our 100% success rate in TQT studies that should we fail to show assay sensitivity we will repeat the study at no cost to our sponsors.To take us up on our promise, contact our Business Development team today to discuss your TQT study needs

Latest news

Single-dose gene silencing cure for fatal heart disease comes one step closer

March 20, 2024
Richmond is delighted to be part of the first large-scale in-human trial of a genetic cure for ATTR Amyloidosis
Read more

How Does Social Time Contribute to a Positive Workplace Culture?

March 13, 2023
Read the blog by Richmond Pharmacology’s Chair of the Social Committee and Head of Marketing, Elizabeth Romano about how being social improves organisational culture and embeds the core values.
Read more

Events

ISA Symposium 2024

29-30 May 2024 
We will be attending the XIX International Symposium on Amyloidosis, taking place in Rochester, Minesota
View event